Table 1.
Detailed description of the ICD-codes used in this study.
Fig 1.
Flow chart of patients and hospital stays included in the analyses between 2008 and 2013.
* Hospital stays related to mRCC are defined by the combination of two set of codes for renal cell carcinoma and for metastases (Primary Diagnosis (PD) = C64 or Related Diagnosis (RD) = C64 or Significant Associated Diagnosis (SAD) = C64) and ((PD = C77 or or C78 or C79) or (RD = C77 or C78 or C79) or (SAD = C77 or C78 or C79)). ** Patients for whom a hospitalisation related to mRCC or a code of metastases were identified in the previous year, or where both metastases and renal cell carcinoma were coded as an SAD (SAD = C64 + SAD = (C77 or C78 or C79)).
Fig 2.
Evolution of the number of patients between 2008 and 2013.
Table 2.
Patient's characteristics.
Table 3.
Distribution of patients according to socio-demographic variables and prescription of expensive drugs.
Table 4.
Multivariate logistic analysis of the impact of socio-demographic variables on the use of expensive drugs.
Table 5.
Distribution of the mean cost per patient and total annual cost according to the type of hospital stay.
Table 6.
Distribution of the annual mean cost per incident patient according to the type of hospital stay and the year of inclusion in the cohort.